Supplier Highlight

Roquette - Advanced Excipients and Drug Delivery Solutions for Pharmaceutical applications

Supplier Highlight

Pharmaceuticals

Explore how IMCD and Roquette collaborate to deliver high-performance excipient systems and functional ingredients for pharmaceutical formulations, supporting a wide range of dosage forms and advanced drug delivery technologies.

About Roquette in Pharmaceutical Applications

Roquette is a global leader in plant-based ingredients, a pioneer of plant proteins, and a leading provider of pharmaceutical excipients. The group addresses current and future societal challenges by offering the best ingredients for health, nutrition, and food markets. These ingredients respond to unique and essential needs, enable healthier lifestyles, and are critical components of life-saving medicines. Founded in 1933, Roquette is a family-owned company that operates in more than 100 countries.

Roquette’s pharmaceutical portfolio is designed to optimise manufacturability, enhance drug performance, and enable innovative therapies. With a deep understanding of formulation challenges, ranging from solubility and stability to release control and patient acceptability, Roquette provides solutions that meet evolving regulatory requirements and market needs.

Discover Roquette’s comprehensive Toolbox for Oral Solid Dosage Forms

- Distributed by IMCD

Tablets & Capsules

Avicel® (Microcrystalline cellulose): The go-to microcrystalline cellulose to produce robust tablets manufactured by direct compression, as well as wet and dry granulation, offering a versatile product range with tailored material properties to provide solutions for all your tabletting challenges, including unique co-processed Avicel grades for enhanced performance with superior flow and compactibility.
Ac Di Sol® (Croscarmellose sodium): The first-choice disintegrant for multiple dosage forms, including immediate-release tablets, ODTs, chewable, and capsules. It can be utilized across a variety of processes, including direct compression, dry and wet granulation, as well as continuous manufacturing processes. An alternative GMO-free grade is available to match your requirements.
Alubra® (Hydrophilic lubricant): A high-performance hydrophilic lubricant for improved production efficiency. It does not adversely impact tableting, disintegration or dissolution performance like other commonly used lubricants.
- Modified Release Matrix PolymersMethocel™ CR: The most widely used polymer in hydrophilic matrix tablets. Designed to deliver robust and consistent modified-release profiles. Available in multiple grades and customized chemical substitutions to control drug release. (Watch our webinar: Matrix (r)evolution - demystifying modified release drug delivery)
- Ethocel™ (Ethylcellulose): Utilized in hydrophobic matrix tablets to provide robust and consistent drug release. Fine particle size options are available to support consistent release profiles and improved tablet properties.
- Polyox™ (Polyethylene oxide polymers): An alternative fast-hydrating hydrophilic matrix polymer that forms swollen hydrogels for controlled drug release (Watch our webinar: Matrix (r)evolution - demystifying modified release drug delivery)

Osmotic Pumps with Polyox™: Non-ionic poly (-ethylene oxide) polymers that are fast-hydrating with high swelling capacity. Available in a range of grades suitable for incorporation into both the push and pull layers of osmotic pump tablets. (Watch our webinar: Osmotic pumps - Powering precision in drug delivery)

Aesthetic & Functional CoatingsMethocel™ LV: A low-viscosity range of HPMC products that are readily soluble and form robust films across all coating production methods.
- Ethocel™: A premium, water-insoluble thermoplastic polymer used to create modified-release barrier membranes. Widely applied in pharmaceutical coatings to control drug diffusion rates, achieve extended-release profiles, mask taste, and protect active ingredients from moisture.
- Aquacoat® ECD: A ready-to-use aqueous coating system based on ethylcellulose. Widely used to create modified-release barrier membrane coatings that control drug diffusion rates, enable extended-release profiles, mask taste, and protect active ingredients from moisture. (Watch our webinar: Rise of the multiparticulates - demystifying modified release drug delivery)

Unique ingredients for liquid and semi-solid dosage forms

The Roquette portfolio provides versatile excipients enabling stability, texture, and performance in liquid systems:

Avicel® RC 591 & CL 611: Co-processed Avicel® products containing MCC and sodium CMC. Used in liquid pharmaceutical formulations to provide unique suspending properties, high yield stress, and thixotropy.
Alginates: Sustainable, natural polysaccharides derived from marine brown algae. They offer a range of viscosities and gel strengths to deliver tailored gelling, stabilizing, and thickening properties.
Seagel™ carrageenans: Sustainable, natural polysaccharides derived from marine red algae. Available in different grades to provide gelling, stabilizing, and thickening functionality.

Versatile solutions for innovative therapeutic formats

Roquette’s excipients support emerging delivery systems and patient-centric formulations:

Alginates (API grade): A unique, custom API grade that provides anti-reflux functionality to support digestive health.
Seagel™ carrageenans: The versatile characteristics of carrageenan gels make them ideal for applications such as soft gel capsules, chewable gummies, therapeutic films, and other innovative dosage forms.
Polyox™: Rapid and extensive swelling make it ideal for gastro-retentive drug delivery platforms. Additionally, it exhibits strong mucoadhesion and excellent organoleptic properties for specialized pharmaceutical products.

Technical highlights & latest developments

Roquette continues to innovate in response to regulatory and formulation challenges:

Low nitrite grades: Supporting manufacturers in mitigating nitrosamine formation risks in pharmaceutical products.
Optimised dissolution profiles: Advanced excipient design enabling predictable and reproducible drug release performance.
Market expertise: Through technical knowledge platforms and application insights, Roquette supports development from early formulation to commercialisation.

IMCD & Roquette: enabling next-generation formulations

At IMCD Pharmaceuticals, our global network of state-of-the-art laboratory facilities and technical experts collaborate closely with partners such as Roquette to develop innovative concepts and dosage forms that meet today’s evolving customer expectations.

Our global technical teams work closely with Roquette to:

Solve complex formulation and process challenges
Optimise manufacturability and scalability
Enhance drug performance and patient adherence
Accelerate time to market with application-ready solutions

By combining Roquette’s advanced excipient portfolio and IMCD's technical expertise, our team enables the development of innovative, high-performance dosage forms.

Discover our solutions with Roquette ingredients:

Connect with IMCD experts to elevate your formulations with Roquette pharma solutions

Ready to explore how Roquette’s innovations can elevate your next pharmaceutical formulation? Get in touch with your local IMCD experts to learn more about the full Roquette portfolio and discover how our global technical teams can support you with osmotic pump delivery systems, nitrosamine risk mitigation strategies, modified-release drug delivery, and much more.

Fill in the form to connect with us and start co-creating products that delight consumers and meet today’s market demands.

Heads up: At CPHI 2026 in Milan, we present our latest solutions fresh from the lab. Come to our booth 1B18 to meet our experts and learn more about Roquette’s solutions.